title: Oxatomide in the treatment of various allergic diseases.
abstract: The use of oral oxatomide (30 to 360 mg per day) for the treatment of allergic conditions of the bronchi, skin and gastro-intestinal tract was investigated in a total of 70 subjects. Therapeutic results were evaluated at intervals ranging between 1 and 16 months. Symptomatic improvements were scored globally, forced expiratory volume in 1 second was measured in asthmatic patients, and the lesions of atopic dermatitis were rated according to a modified Clendening scale. The results suggest that oxatomide was particularly effective in the treatment of allergic rhinitis and skin allergies. Allergic asthma responded fairly well in patients with a short history of disease and gastro-intestinal conditions reacted moderately, with haemorrhagic rectitis responding better than gastritis. These findings warrant further controlled trials of oxatomide in such conditions.
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001249:Asthma / Q000188:drug therapy; D002648:Child; D002675:Child, Preschool; D005260:Female; D005767:Gastrointestinal Diseases / Q000188:drug therapy; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D012140:Respiratory Tract Diseases / Q000188:drug therapy; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy; D012871:Skin Diseases / Q000188:drug therapy; D013997:Time Factors
chemical_list: D010879:Piperazines; C015408:oxatomide